Cannvalate has entered into an agreement with Tetra Bio-Pharma to conduct clinical trials of the Canadian firm’s cannabinoid drug candidates in Australia through its wholly owned clinical research organisation Ingenu.
As part of the deal, co-founder and CEO Dr Sud Agarwal will act as a special advisor to Tetra’s CEO and board of directors. Cannvalate will also acquire common shares in Tetra on a private placement basis, through seven distinct tranches, for aggregate proceeds of C$7.5m.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.